In the past, I wrote that a newly drug was underinvestigated in a clinical trial for the treatment of Alzheimer's disease. Conventional drugs have only an effect to slow the progress of the disease superficially. But Solanezumab is considered to reverse the symptoms of dementia, through taking away beta amyloids from the central nerve tissue, theoretically.
My past entry: Solanezumab, challenge to Alzheimer's disease
So far, there is no apparent evidence that Solanezumab has a significant benefit. But, Illy Lilly still believes its value as an innovational drug. The clinical trial is still ongoing.
Business Insider: A big Alzheimer's drug trial is about to offer real hope for treating the disease — or crush it
On the other hand, there are other possibilities to overcome Alzheimer's disease. It was found that CT1812, a newly developed compound, could negate the adverse effects of beta amyloid had been found in mice to negate the effects of the toxic protein amyloid-beta. It is unique that CT1812 does not eliminate amyloid but protects brain neurons from its attack.
The Age: New drug could slow or halt Alzheimer's, says leader of clinical trials
I hardly believe that these new drugs will be successful, as several similar attempts have failed to show the certain effect so far. Nonetheless, I dream the era everyone is relieved from the fear of losing memory. If it is realized, it is certain that the developer of the drug will get great respect and the astronomical amount of money.
No comments:
Post a Comment